Dividend Champions: AbbVie and Visa's Unshakable Promise for Lifetime Payouts

Investors often flock to dividend stocks for several compelling reasons. Some are drawn by the passive income, others value the reinvestment potential for long-term growth, and many appreciate the reliability of companies that consistently issue and increase payouts. Naturally, dividend cuts are far from desirable—most investors seek payments that stretch indefinitely into the future. While many income stocks might eventually suspend or reduce their dividends, a select few appear robust enough to offer lifetime payments. In this light, let's delve into two notable examples: AbbVie (NYSE: ABBV) and Visa (NYSE: V).

AbbVie (NYSE: ABBV)

Initially a part of Abbott Laboratories, AbbVie made its independent debut in 2013. Known prominently for its blockbuster rheumatoid arthritis drug, Humira, AbbVie's enduring appeal also lies in its history of consistent dividend hikes. As Humira lost its patent protection in the U.S. last year, concerns regarding the sustainability of AbbVie's payouts naturally arose among shareholders. Despite this shift, AbbVie showcases its resilience beyond Humira.

Although revenues and earnings took a hit due to Humira's exclusivity loss, AbbVie is banking on two promising immunology drugs, Skyrizi and Rinvoq, to bridge the gap. Management anticipates these drugs will generate a combined revenue of $27 billion by 2027. This forecast surpasses Humira's peak annual sales, underscoring AbbVie's innovative prowess in developing new medicines. The company has meticulously planned for Humira's patent cliff, and undoubtedly, it will strategize similarly for Skyrizi and Rinvoq in the future. Hence, AbbVie's long-term promise lies in its culture of innovation, a defining trait that could sustain dividends for a lifetime or more.

Even amidst Humira’s challenges, AbbVie has maintained its dividend growth trajectory. Since its inception, the dividend has soared by an impressive 288%. With a forward yield of 3.6% and a reasonable cash payout ratio of just under 49%, AbbVie's stock remains an enticing option for long-term income-focused investors. Furthermore, by virtue of its historical connection to Abbott Laboratories, AbbVie proudly stands as a Dividend King, having increased its payouts for 52 consecutive years.

Visa (NYSE: V)

Carrying cash and checks can be quite the hassle, particularly in an era dominated by digital transactions. Visa has been at the forefront of this transition, operating one of the world's premier payment networks. Unlike card issuers, Visa sidesteps default risks by serving as an intermediary between banks and merchants. This strategic position allows Visa to capitalize on the network effect: as more merchants join its ecosystem, it becomes increasingly attractive to consumers, and vice versa.

Visa's business model is a cash cow, pocketing fees from every transaction facilitated by its network. Unsurprisingly, Visa has consistently reported stellar financial results, with future prospects looking bright. The company envisions a $20 trillion addressable market, with a significant portion still tied up in cash and checks. The runway for growth remains extensive.

In terms of dividends, Visa might not boast an eye-catching yield at just 0.8%, but the real story is in its growth. Over the past decade, Visa's dividend has surged by an astonishing 420%. Despite this rapid increase, the company's cash payout ratio sits at a conservative 20%, indicating substantial room to boost dividends further. Coupled with Visa's robust business model and promising long-term opportunities, the stock stands as a reliable long-term dividend investment.